Investing
Top Analyst Upgrades and Downgrades: Celgene, DigitalGlobe, Micron, Paychex, Bed Bath & Beyond and Many More
Published:
Last Updated:
Stocks were indicated mixed on Thursday after a sharp rally on Wednesday. This is a shortened trading day due to Christmas coming tomorrow, and investors and traders who are around should expect much lighter trading volumes. The stock market is still fighting for a positive 2015. The trend that has prevailed for over four years now is that investors have bought every single market pullback.
24/7 Wall St. reviews dozens of analyst research reports each morning of the week to find new investing and trading ideas for its readers. Some of these analyst reports cover stocks to buy. Others cover stocks to sell or avoid. These are the top analyst calls for Thursday, December 24, 2015.
Bed Bath & Beyond
Credit Suisse maintained a Neutral rating on Bed Bath & Beyond Inc. (NASDAQ: BBBY), but the firm lowered its estimates and cut the price target to $51 from $53. Many analysts lowered ratings or target prices on Wednesday after its warning.
Bed Bath & Beyond closed down 4.6% at $48.97 Wednesday, after its sales and earnings warning, and it put in a new 52-week low of $47.98.
Celgene
Celgene Corp. (NASDAQ: CELG) was reiterated as Buy with a price target of $155 (versus a $122.07 prior close, after a gain of 9.8%) at Argus. The firm said that Celgene’s patent settlement news should bring unfettered patent protection for the drug Revlimid through 2022 and strengthens its revenue prospects.
Celgene has a consensus analyst price target of $142.75 and a 52-week trading range of $92.98 to $140.72.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
